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Schmitt-Grohe´ et al.1 show that Montelukast reduces
eosinophilic inflammation in cystic fibrosis (CF). However,
we failed to demonstrate that a significant clinical benefit
after a 21-day treatment course occurred. In the current
submission, we report the effects of long-term treatment
with Montelukast of the original study population of
Schmitt-Grohe´ et al.1
Pulmonary function tests (FEV1, MEF25), total eosinophil
count, eosinophil cationic protein (ECP), IgE as well as
sputum samples or pharyngeal swabs were assessed at the
beginning of the study (PRE) and after a long-term
treatment course (POST). Differences were evaluated using
the Wilcoxon test for paired samples.
Follow-up data was available from 15 of the original 16
patients (9 boys/6 girls; age (PRE/POST 8.0/13.0 y) with a
median observation period of 5.0 yr (3.48–5.42 yr). There
was a significant decrease in total eosinophil count (PRE/
POST 150/0 (/ml); Po0.05) and ECP (PRE/POST (mg/l)
13.55/8.1; Po0.023) and no change in IgE (PRE/POST
34.6/49.6 kU/l; n.s.). Overall there was no change in FEV1
(PRE/POST (%) 92/93;n.s.), whereas a significant increase of
MEF25 (PRE/POST (%) 55/89; Po0.012) was observed.
Surprisingly, 6 of the originally 7 chronically Pseudomonas
aeruginosa infected patients were repeatedly negative (Po
0.031) in sputum.
Our data show that eosinophilic inflammation in CF was
consistently lower under Montelukast than before treat-
ment. Interestingly, there was no deterioration of lung
function and a significant increase in MEF25, suggesting a
beneficial role of Montelukast to prevent remodelling and
small airway disease. In addition, there was a significant
decrease in P. aeruginosa colonization after treatment with
Montelukast in combination with antibiotic treatment. This
finding was totally unexpected and lead to the conjecture
that Montelukast might help to prevent P. aeruginosa
colonization. The mode of action is speculative: The
increase in MEF 25 reflects improved patency of small
airways due to Montelukast. Interestingly it was recently
shown that Montelukast improves small airway disease inont matter & 2006 Elsevier Ltd. All rights reserved.
2006.07.006asthmatic subjects detected by high-resolution computer
tomography.2 Moreover it is well documented that narrow-
ing of small airways in addition to sticky secretion creates a
micromilieu that favors growth of P. aeruginosa. There is
also evidence that respiratory viral infections3 cause injury
to respiratory epithelium, which leads to increased adher-
ence of bacteria to pharyngeal cells. Montelukast amelio-
rates symptoms following respiratory viral infections.4 In
addition, Bisgaard et al.5 have shown a decreased ciliary
beat frequency (CBF) due to cysteinyl leukotrienes (cysLT).
In conclusion, long-term double-blind placebo-controlled
trials are needed to show whether Montelukast can improve
small airway disease and prevents (in combination with
antibiotic therapy) adherence of P. aeruginosa in CF patients.
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